Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 DATA SUPPORT INITIATION OF A COMBINATION COHORT IN THE ONGOING PHASE 1 CLINICAL TRIAL TO EVALUATE ARV-393 PLUS GLOFITAMAB AS A CHEMOTHERAPY-FREE COMBINATION APPROACH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); INITIATION EXPECTED IN 2026  NEW HAVEN, CONN., DEC. 06, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED PRECLINICAL DATA FOR ARV-393, A PROTAC BCL6 DEGRADER, IN COMBINATION WITH GLOFITAMAB, A CD20CD3 BISPECIFIC ANTIBODY, PRESENTED IN A POSTER AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION, HELD DECEMBER 69, 2025, IN ORLANDO, FLORIDA.

ARVINAS PRESENTS PRECLINICAL DATA SUPPORTING MECHANISTIC SYNERGIES AND ENHANCED ANTITUMOR ACTIVITY WITH THE COMBINATION OF ARV-393 AND GLOFITAMAB AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING AND EXPOSITION

NEW HAVEN, CONN., NOV. 26, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT NOAH BERKOWITZ, M.D., PH.D., CHIEF MEDICAL OFFICER, AND ANDREW SAIK, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON THURSDAY, DECEMBER 4 AT 11:00 A.M. ET IN NEW YORK.

ARVINAS TO PRESENT AT PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

NEW HAVEN, CONN., NOV. 24, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT MULTIPLE ABSTRACTS ON VEPDEGESTRANT (ARV-471) HAVE BEEN ACCEPTED FOR PRESENTATION AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS), TAKING PLACE DECEMBER 912, 2025 IN SAN ANTONIO, TEXAS. VEPDEGESTRANT IS A NOVEL INVESTIGATIONAL PROTAC ESTROGEN RECEPTOR (ER) DEGRADER WHICH IS BEING DEVELOPED WITH PFIZER INC. (NYSE: PFE) AS A POTENTIAL MONOTHERAPY FOR ESTROGEN RECEPTOR POSITIVE (ER+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER WITH ESTROGEN RECEPTOR 1 (ESR1) MUTATIONS IN THE SECOND LINE-PLUS SETTING.* ONGOING STUDIES ARE ALSO EVALUATING VEPDEGESTRANT AS A MONOTHERAPY AND AS PART OF COMBINATION THERAPY FOR ER+/HER2- BREAST CANCER.

ARVINAS ANNOUNCES DATA PRESENTATIONS FROM THE VEPDEGESTRANT (ARV-471) CLINICAL DEVELOPMENT PROGRAM AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)

 PRESENTED POSITIVE DATA FROM PHASE 1 CLINICAL TRIALS WITH ARV-102 IN HEALTHY VOLUNTEERS AND PATIENTS WITH PARKINSON'S DISEASE   PRESENTED PRECLINICAL DATA FROM ARV-806 DEMONSTRATING ROBUST AND DIFFERENTIATED ACTIVITY IN MODELS OF KRAS G12D-MUTATED CANCER   PRESENTED PRECLINICAL DATA FROM ARV-027 DEMONSTRATING ROBUST DEGRADATION OF POLYQ-AR IN MUSCLE, SUPPORTING FURTHER EVALUATION AS A POTENTIALLY DISEASE-MODIFYING THERAPY IN SBMA   ANNOUNCED AGREEMENT WITH PFIZER TO JOINTLY SELECT A THIRD PARTY FOR THE COMMERCIALIZATION AND POTENTIAL FURTHER DEVELOPMENT OF VEPDEGESTRANT   COMPANY TO HOST CONFERENCE CALL TODAY AT 8:00 A.M. ET  NEW HAVEN, CONN.

ARVINAS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW HAVEN, CONN., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT PRECLINICAL DATA FOR PROTAC BCL6 DEGRADER ARV-393, IN COMBINATION WITH GLOFITAMAB, A CD20XCD3 BISPECIFIC ANTIBODY, WILL BE PRESENTED IN A POSTER PRESENTATION AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING, BEING HELD DECEMBER 69, 2025, IN ORLANDO, FLORIDA.

ARVINAS TO PRESENT PRECLINICAL DATA FOR ARV-393 AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

NEW HAVEN, CONN., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES.

ARVINAS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

NEW HAVEN, CONN., OCT. 29, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT MANAGEMENT WILL REVIEW FINANCIAL RESULTS FROM THE THIRD QUARTER OF 2025 AND PROVIDE A CORPORATE UPDATE DURING A LIVE WEBCAST ON WEDNESDAY, NOVEMBER 5, 2025 AT 8:00 A.M.

ARVINAS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 5, 2025

 IN VIVO, ARV-806 DEMONSTRATED ROBUST AND DURABLE KRAS G12D DEGRADATION, LEADING TO SIGNIFICANT TUMOR GROWTH INHIBITION IN MODELS OF PANCREATIC, COLORECTAL, AND LUNG CANCER 

ARVINAS PRESENTS PRECLINICAL DATA FOR ARV-806 DEMONSTRATING ROBUST AND DIFFERENTIATED ACTIVITY IN MODELS OF KRAS G12D-MUTATED CANCER AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

NEW HAVEN, CONN., OCT. 22, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT PRECLINICAL DATA FOR ARV-806, A PROTAC KRAS G12D DEGRADER, WILL BE PRESENTED AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS IN BOSTON, MASSACHUSETTS.

ARVINAS TO PRESENT PRECLINICAL DATA FOR ARV-806, A PROTAC KRAS G12D DEGRADER, AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

 DATA DEMONSTRATED THAT VEPDEGESTRANT MAINTAINED PATIENTS' QUALITY OF LIFE FOR STATISTICALLY SIGNIFICANTLY LONGER AND DELAYED WORSENING OF OVERALL HEALTH, DAILY FUNCTIONING, AND SYMPTOMS, INCLUDING PAIN, COMPARED TO FULVESTRANT  NEW HAVEN, CONN., OCT. 20, 2025 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), TODAY ANNOUNCED NEW PATIENT-REPORTED OUTCOMES (PRO) DATA FROM THE PHASE 3 VERITAC-2 CLINICAL TRIAL (NCT05654623) EVALUATING VEPDEGESTRANT, WHICH ARE BEING PRESENTED IN A MINI ORAL SESSION AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS.

PATIENT-REPORTED OUTCOMES FROM VERITAC-2 CLINICAL TRIAL SUPPORT CLINICAL BENEFIT OF VEPDEGESTRANT IN PATIENTS WITH ESR1-MUTATED, ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE-BASED THERAPY

Arvinas, Inc.

ARVN

Price

Financial Reports

No items found.

Press Releases

Arvinas, Inc.

ARVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARVN